Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 7/20 | 0.45 |
| ▸ | PTPN7 | P35236 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4169864 | 1.00 | HMGCR (0.45) | HMGCRPTPN7TSHRTHRBRECQL | |
| SCHEMBL3023466 | 0.97 | HMGCR (0.43) | HMGCRPTPN7TSHRTHRBRECQL | |
| SCHEMBL59533 | 0.95 | HMGCR (0.41) | HMGCRPTPN7TSHRTHRBRECQL | |
| SCHEMBL2571403 | 0.84 | TSHR (0.38) | HMGCRPTPN7TSHR | |
| SCHEMBL5168900 | 0.83 | HMGCR (0.41) | HMGCRPTPN7TSHRTHRBRECQL | |
| SCHEMBL5170459 | 0.83 | HMGCR (0.41) | HMGCRPTPN7TSHRTHRBRECQL | |
| SCHEMBL5169808 | 0.83 | HMGCR (0.41) | HMGCRPTPN7TSHRTHRBRECQL | |
| SCHEMBL2118927 | 0.82 | HMGCR (0.43) | HMGCRPTPN7TSHRTHRBRECQL | |
| SCHEMBL5167000 | 0.82 | HMGCR (0.43) | HMGCRPTPN7TSHRTHRBRECQL | |
| SCHEMBL5166824 | 0.82 | HMGCR (0.43) | HMGCRPTPN7TSHRTHRBRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11464770-B2 | Anticancer pharmaceutical composition | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-10-11 | — | — | US | disclosed |
| US-20210315879-A1 | ANTICANCER PHARMACEUTICAL COMPOSITION | NATIONAL CANCER CENTER (KR) | 2021-10-14 | — | — | US | disclosed |
| EP-3492082-A1 | ANTICANCER PHARMACEUTICAL COMPOSITION | National Cancer Center (KR) | 2019-06-05 | — | — | EP | disclosed |
| CN-109715159-A | Anticancer medicine composition | 国立癌症中心 | 2019-05-03 | — | — | CN | disclosed |
| CN-109715607-A | Compounds that inhibit the formation of the C-MYC/MAX/DNA complex | 国立癌症中心 | 2019-05-03 | — | — | CN | disclosed |
| WO-2013072758-A1 | PYRIMIDINE DIOL AMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2013-05-23 | — | — | WO | disclosed |
| EP-1487436-A4 | COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS | SIGNAL PHARM INC (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1487436-A1 | COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS | Signal Pharmaceuticals, Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003075917-A1 | COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11464770-B2 | Anticancer pharmaceutical composition | MYC, MYCBP, TP53 | HMGCR 733/4885PTPN7 2945/4885TSHR 4683/4885 |
| US-20210315879-A1 | ANTICANCER PHARMACEUTICAL COMPOSITION | MYC, MYCBP, TP53 | HMGCR 733/4885PTPN7 2945/4885TSHR 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.